SOPHiA GENETICS and AstraZeneca have expanded their partnership to use artificial intelligence (AI) for improving outcomes for breast cancer patients.
The collaboration will leverage SOPHiA’s AI Factories to generate evidence on the efficacy and real-world impact of breast cancer therapies, to optimise outcomes.
The AI Factories, based on advanced computing protocols and diverse multimodal datasets, provide predictive insights into patient prognosis and treatment response.
AstraZeneca will employ the AI Factories to analyse multimodal healthcare data, including genomics, imaging, and clinical information.
AstraZeneca chief AI and data scientist Jorge Reis-Filho said: “At AstraZeneca, a core component of our AI strategy has been rooted in the deployment of frontier AI solutions across oncology clinical development.
“Fine tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer.”
The partnership aims to generate insights that optimise breast cancer treatment outcomes.
It will also focus on generating real-world evidence in Europe and North America.
The initiative aims to uncover key drivers of treatment efficacy, address knowledge gaps, and enhance clinical decision-making through deeper insights.
SOPHiA GENETICS president Ross Muken said: “We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications.
“Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI.”
Recently, AstraZeneca announced a $50bn investment in the US by 2030, to support the global medicines manufacturing and research sectors.
A significant part of this investment is a new manufacturing facility in Virginia.
The new facility will produce drug substances for AstraZeneca’s weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9, and others.
